Navigation Links
Trial seeks improved lung-cancer screening by combining imaging and biomarkers
Date:5/3/2012

amatically improves a patient's curative treatment options. Five-year survival for patients with advanced, stage IV disease is only 1 percent, while those whose cancer is detected early at stage I have a 70 to 80 percent of surviving five years. Five year-survival of all lung cancer in the United States is only 16 percent, because the disease is usually detected at an advanced stage when it becomes symptomatic.

"Early detection of cancer could dramatically improve survival and reduce the terrible toll it takes on people today," said Debra Dyer, MD, radiologist at National Jewish Health and co-principal investigator on the study. "We believe this study may demonstrate an effective method for doing just that."

The trial will screen 1,600 participants over 4 years. They will receive both the EarlyCDT-Lung blood test and a low-dose CT scan at no charge. Particpants need to be 50-75 years of age, have a smoking history of at least 20 pack-years (equivalent to a pack a day for 20 years), and be a current or former smoker who quit fewer than 10 years ago. Those who have a history of cancer other than skin cancer, serious illness that limits their life expectancy to less than 5 years, or currently use oxygen to breathe are not eligible for the study.


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
4. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
5. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
6. Can industrial parks be more environmentally friendly?
7. Recruitment starts on MS hookworm trial
8. First vaccine against fatal visceral leishmaniasis enters clinical trial
9. Using online patient communities and new trial approaches to optimize clinical research
10. Sustainable land use strategies to support bioenergy described in Industrial Biotechnology journal
11. First industrial-scale foam forming research environment for forest sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... Ore. In ecosystems around the world, the decline of ... is changing the face of landscapes from the tropics to ... published today in the journal Science shows for ... by humans and loss of prey combine to create global ...
... A team of scientists at LSU Health Sciences Center ... of E6-associated protein (E6AP), an enzyme that acts as a ... time, that the active form of E6AP is composed of ... the ability of nerve cells to "rewire" themselves in response ...
... new technology to squeeze more energy from the fuel release ... power plants do, according to a new analysis accepted for ... of the American Geophysical Union. The so-called "combined cycle" natural ... sulfur dioxide, which can worsen air quality. "Since more ...
Cached Biology News:Loss of large carnivores poses global conservation problem 2Loss of large carnivores poses global conservation problem 3LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer 2New study: US power plant emissions down 2
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... the fiscal year ended December 31, 2007., ... its EAA(TM) Endotoxin,Activity Assay, the only FDA ... is a systemic response to bacterial toxins ...
... CLARA, Calif., March 7 Finesse Solutions, LLC, ... sciences process,applications, and Nova Biomedical, Waltham, MA, a ... TruBio(TM) OS plug-in,for OPC connectivity between TruBio(TM) OS ... Basic 2 analyzers. Both companies confirmed that a,TruBio(TM) ...
... SAN DIEGO, March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... will release its,fourth quarter and full year ended ... market on Wednesday, March 12, 2008., Cadence ...
Cached Biology Technology:Spectral announces 2007 financial results 2Spectral announces 2007 financial results 3Spectral announces 2007 financial results 4Spectral announces 2007 financial results 5Spectral announces 2007 financial results 6Spectral announces 2007 financial results 7Spectral announces 2007 financial results 8Spectral announces 2007 financial results 9Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
...
MultiWash III w/ 12-portStandard Manifold...
... 5 ml. The same high performance ... columns for fast, reliable purification of ... 5/50 GL, XK 16/20, or other ... required.Extremely useful for exploiting either the ...
...
Biology Products: